Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| D013577 | Syndrome NIH | 0.09 |
| D012127 | Respiratory Distress Syndrome, Newborn NIH | 0.08 |
| D055371 | Acute Lung Injury NIH | 0.08 |
| Name (Synonyms) | Correlation |
|---|
Navigate: Correlations HPO
There is one clinical trial.
This study is to evaluate to compare the pharmacokinetics, safety, tolerability, and immunogenicity of two formulations of SB5 in healthy male subjects.
Description: Area under the concentration-time curve from time zero to infinity
Measure: AUCinf Time: Day 1 to Day 57Description: Maximum serum concentration
Measure: Cmax Time: Day 1 to Day 57Description: Area under the concentration-time curve from time zero to the last quantifiable concentration
Measure: AUClast Time: Day 1 to Day 57Description: Time to reach Cmax
Measure: Tmax Time: Day 1 to Day 57Description: Apparent volume of distribution during the terminal phase
Measure: Vz/F Time: Day 1 to Day 57Description: Terminal rate constant
Measure: λz Time: Day 1 to Day 57Description: Terminal half-life
Measure: t1/2 Time: Day 1 to Day 57Description: Apparent total body clearance
Measure: CL/F Time: Day 1 to Day 57Description: Percentage of AUCinf due to extrapolation from time of last measurable concentration (Tlast) to infinity
Measure: %AUCextrap Time: Day 1 to Day 57Description: Experience at least 1 TEAE
Measure: Incidence of treatment-emergent adverse events (TEAEs) Time: Day 1 to Day 57Description: Experience at least 1 SAE
Measure: Incidence of serious adverse events (SAEs) Time: Day 1 to Day 57Description: Incidence of ADAs to adalimumab
Measure: Incidence of anti-drug antibodies (ADAs) Time: Day 1 to Day 57Description: Incidence of NAbs to adalimumab
Measure: Incidence of neutralising antibodies (NAbs) Time: Day 1 to Day 57Alphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports